Can a hormone drug help restore skin color in vitiligo?
NCT ID NCT07437560
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 study tests whether adding Melanotan II (a synthetic hormone-like drug) to standard narrowband UV-B light therapy helps restore skin color in adults with stable nonsegmental vitiligo. About 60 participants will receive either the drug or a placebo, plus light therapy, for several months. Researchers will measure changes in skin pigmentation and track how quickly repigmentation occurs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Melanotan II (a synthetic hormone-like drug) plus narrowband UV-B phototherapy
What this could lead to
If it works, this could offer a new treatment option to restore skin color in people with stable vitiligo.
What could go wrong
This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may cause side effects or not improve repigmentation more than light therapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONSEGMENTAL VITILIGO are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
Contact Phone: •••-•••-•••• Email: •••••@•••••